跳至主要内容
临床试验/JPRN-UMIN000004375
JPRN-UMIN000004375已完成未知

Study on preventive effect of risedronate administration on aromatase inhibitor-induced bone mineral loss in the endoclinical therapy for postmenopausal breast cancer patients - Effect of risedronate on aromatase inhibitor-induced bone mineral loss in the postmenopausal breast cancer

Graduate School of Medicine Kyoto University0 个研究点目标入组 64 人开始时间: 2010年11月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Inflamatory breast cancer 2) Hypersensitivity to any reagents used in this trial. 3) Serious complications 4) Excess alcohol consumption 5) Habitual smoker 6) Family history of hip joint fracture 7) Active dental and/ or periodontal disease which requires treatment 8) Withdrawal of informed concent 9) Patients who are judged inappropriate for the clinical trial by doctors

研究者

发起方
Graduate School of Medicine Kyoto University

相似试验